GATA binding protein 6 (GATA6) is co-amplified with PIK3CA in patients with esophageal adenocarcinoma and is linked to neoadjuvant therapy

PURPOSE: Driver mutations are typically absent in esophageal adenocarcinoma (EAC). Mostly, oncogenes are amplified as driving molecular events (including GATA6-amplification in 14% of cases). However, only little is known about its biological function and clinical relevance. METHODS: We examined a l...

Descripción completa

Detalles Bibliográficos
Autores principales: Plum, Patrick Sven, Löser, Heike, Zander, Thomas, Essakly, Ahlem, Bruns, Christiane J., Hillmer, Axel M., Alakus, Hakan, Schröder, Wolfgang, Büttner, Reinhard, Gebauer, Florian, Quaas, Alexander
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Original Article – Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7954758/
https://www.ncbi.nlm.nih.gov/pubmed/33300112
http://dx.doi.org/10.1007/s00432-020-03486-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7954758/
https://www.ncbi.nlm.nih.gov/pubmed/33300112
http://dx.doi.org/10.1007/s00432-020-03486-2

Ejemplares similares